MedImmune gets green light for FluMist

Head 'em up, move 'em out. MedImmune says it's cleared up its FluMist manufacturing problems, just in time to ship the product for this year's flu season. The FDA had warned the company in May for "significant deviations from current good manufacturing practice" at its U.K. facility, where FluMist is made. At issue were mold and bacteria found in the plant (but not in the vaccine itself).

The manufacturing clearance also opens the way for MedImmune to pursue approval of FluMist in children under five. Just before the manufacturing warning, an FDA advisory panel had said that the company's flu preventive works in that age group, though they were unsure whether it would be safe for kids under two.

- see this release
- and here's the report from The Washington Post

Related Articles:
MedImmune wins backing for expanded FluMist use. Report
MedImmune boosted by new data on FluMist. Report
MedImmune touts new FluMist version. Report
FluMist disappoints MedImmune yet again. Report 

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.